Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. Wazni, O., Marrouche, N., Martin, D., Verma, A., Bhargava, M., Saliba, W., Bash, D., Schweikert, R., Brachmann, J., Gunther, J., Gutleben, K., Pisano, E., Potenza, D., Fanelli, R., Raviele, A., Themistoclakis, S., Rossillo, A., Bonso, A., & Natale, A. JAMA, 293(21):2634--2640, June, 2005. bibtex @Article{RSM:Waz2005b,
author = "O.M. Wazni and N.F. Marrouche and D.O. Martin and A.
Verma and M. Bhargava and W. Saliba and D. Bash and R.
Schweikert and J. Brachmann and J. Gunther and K.
Gutleben and E. Pisano and D. Potenza and R. Fanelli
and A. Raviele and S. Themistoclakis and A. Rossillo
and A. Bonso and A. Natale",
title = "Radiofrequency ablation vs antiarrhythmic drugs as
first-line treatment of symptomatic atrial
fibrillation: a randomized trial.",
journal = "JAMA",
year = "2005",
month = jun,
volume = "293",
number = "21",
pages = "2634--2640",
robnote = "afib CONTEXT: Treatment with antiarrhythmic drugs and
anticoagulation is considered first-line therapy in
patients with symptomatic atrial fibrillation (AF).
Pulmonary vein isolation (PVI) with radiofrequency
ablation may cure AF, obviating the need for
antiarrhythmic drugs and anticoagulation. OBJECTIVE: To
determine whether PVI is feasible as first-line therapy
for treating patients with symptomatic AF. DESIGN,
SETTING, AND PARTICIPANTS: A multicenter prospective
randomized study conducted from December 31, 2001, to
July 1, 2002, of 70 patients aged 18 to 75 years who
experienced monthly symptomatic AF episodes for at
least 3 months and had not been treated with
antiarrhythmic drugs. INTERVENTION: Patients were
randomized to receive either PVI using radiofrequency
ablation (n=33) or antiarrhythmic drug treatment
(n=37), with a 1-year follow-up. MAIN OUTCOME MEASURES:
Recurrence of AF, hospitalization, and quality of life
assessment. RESULTS: Two patients in the antiarrhythmic
drug treatment group and 1 patient in the PVI group
were lost to follow-up. At the end of 1-year follow-up,
22 (63\%) of 35 patients who received antiarrhythmic
drugs had at least 1 recurrence of symptomatic AF
compared with 4 (13\%) of 32 patients who received PVI
(P<.001). Hospitalization during 1-year follow-up
occurred in 19 (54\%) of 35 patients in the
antiarrhythmic drug group compared with 3 (9\%) of 32
in the PVI group (P<.001). In the antiarrhythmic drug
group, the mean (SD) number of AF episodes decreased
from 12 (7) to 6 (4), after initiating therapy (P =
.01). At 6-month follow-up, the improvement in quality
of life of patients in the PVI group was significantly
better than the improvement in the antiarrhythmic drug
group in 5 subclasses of the Short-Form 36 health
survey. There were no thromboembolic events in either
group. Asymptomatic mild or moderate pulmonary vein
stenosis was documented in 2 (6\%) of 32 patients in
the PVI group. CONCLUSION: Pulmonary vein isolation
appears to be a feasible first-line approach for
treating patients with symptomatic AF. Larger studies
are needed to confirm its safety and efficacy.",
bibdate = "Thu Jun 28 00:49:02 2007",
}
Downloads: 0
{"_id":"wH3p7tLb6vKaqCNr2","bibbaseid":"wazni-marrouche-martin-verma-bhargava-saliba-bash-schweikert-etal-radiofrequencyablationvsantiarrhythmicdrugsasfirstlinetreatmentofsymptomaticatrialfibrillationarandomizedtrial-2005","downloads":0,"creationDate":"2016-07-01T21:38:42.804Z","title":"Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.","author_short":["Wazni, O.","Marrouche, N.","Martin, D.","Verma, A.","Bhargava, M.","Saliba, W.","Bash, D.","Schweikert, R.","Brachmann, J.","Gunther, J.","Gutleben, K.","Pisano, E.","Potenza, D.","Fanelli, R.","Raviele, A.","Themistoclakis, S.","Rossillo, A.","Bonso, A.","Natale, A."],"year":2005,"bibtype":"article","biburl":"http://www.sci.utah.edu/~macleod/Bibtex/biglit.bib","bibdata":{"bibtype":"article","type":"article","author":[{"firstnames":["O.M."],"propositions":[],"lastnames":["Wazni"],"suffixes":[]},{"firstnames":["N.F."],"propositions":[],"lastnames":["Marrouche"],"suffixes":[]},{"firstnames":["D.O."],"propositions":[],"lastnames":["Martin"],"suffixes":[]},{"firstnames":["A."],"propositions":[],"lastnames":["Verma"],"suffixes":[]},{"firstnames":["M."],"propositions":[],"lastnames":["Bhargava"],"suffixes":[]},{"firstnames":["W."],"propositions":[],"lastnames":["Saliba"],"suffixes":[]},{"firstnames":["D."],"propositions":[],"lastnames":["Bash"],"suffixes":[]},{"firstnames":["R."],"propositions":[],"lastnames":["Schweikert"],"suffixes":[]},{"firstnames":["J."],"propositions":[],"lastnames":["Brachmann"],"suffixes":[]},{"firstnames":["J."],"propositions":[],"lastnames":["Gunther"],"suffixes":[]},{"firstnames":["K."],"propositions":[],"lastnames":["Gutleben"],"suffixes":[]},{"firstnames":["E."],"propositions":[],"lastnames":["Pisano"],"suffixes":[]},{"firstnames":["D."],"propositions":[],"lastnames":["Potenza"],"suffixes":[]},{"firstnames":["R."],"propositions":[],"lastnames":["Fanelli"],"suffixes":[]},{"firstnames":["A."],"propositions":[],"lastnames":["Raviele"],"suffixes":[]},{"firstnames":["S."],"propositions":[],"lastnames":["Themistoclakis"],"suffixes":[]},{"firstnames":["A."],"propositions":[],"lastnames":["Rossillo"],"suffixes":[]},{"firstnames":["A."],"propositions":[],"lastnames":["Bonso"],"suffixes":[]},{"firstnames":["A."],"propositions":[],"lastnames":["Natale"],"suffixes":[]}],"title":"Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.","journal":"JAMA","year":"2005","month":"June","volume":"293","number":"21","pages":"2634--2640","robnote":"afib CONTEXT: Treatment with antiarrhythmic drugs and anticoagulation is considered first-line therapy in patients with symptomatic atrial fibrillation (AF). Pulmonary vein isolation (PVI) with radiofrequency ablation may cure AF, obviating the need for antiarrhythmic drugs and anticoagulation. OBJECTIVE: To determine whether PVI is feasible as first-line therapy for treating patients with symptomatic AF. DESIGN, SETTING, AND PARTICIPANTS: A multicenter prospective randomized study conducted from December 31, 2001, to July 1, 2002, of 70 patients aged 18 to 75 years who experienced monthly symptomatic AF episodes for at least 3 months and had not been treated with antiarrhythmic drugs. INTERVENTION: Patients were randomized to receive either PVI using radiofrequency ablation (n=33) or antiarrhythmic drug treatment (n=37), with a 1-year follow-up. MAIN OUTCOME MEASURES: Recurrence of AF, hospitalization, and quality of life assessment. RESULTS: Two patients in the antiarrhythmic drug treatment group and 1 patient in the PVI group were lost to follow-up. At the end of 1-year follow-up, 22 (63%) of 35 patients who received antiarrhythmic drugs had at least 1 recurrence of symptomatic AF compared with 4 (13%) of 32 patients who received PVI (P<.001). Hospitalization during 1-year follow-up occurred in 19 (54%) of 35 patients in the antiarrhythmic drug group compared with 3 (9%) of 32 in the PVI group (P<.001). In the antiarrhythmic drug group, the mean (SD) number of AF episodes decreased from 12 (7) to 6 (4), after initiating therapy (P = .01). At 6-month follow-up, the improvement in quality of life of patients in the PVI group was significantly better than the improvement in the antiarrhythmic drug group in 5 subclasses of the Short-Form 36 health survey. There were no thromboembolic events in either group. Asymptomatic mild or moderate pulmonary vein stenosis was documented in 2 (6%) of 32 patients in the PVI group. CONCLUSION: Pulmonary vein isolation appears to be a feasible first-line approach for treating patients with symptomatic AF. Larger studies are needed to confirm its safety and efficacy.","bibdate":"Thu Jun 28 00:49:02 2007","bibtex":"@Article{RSM:Waz2005b,\n author = \"O.M. Wazni and N.F. Marrouche and D.O. Martin and A.\n Verma and M. Bhargava and W. Saliba and D. Bash and R.\n Schweikert and J. Brachmann and J. Gunther and K.\n Gutleben and E. Pisano and D. Potenza and R. Fanelli\n and A. Raviele and S. Themistoclakis and A. Rossillo\n and A. Bonso and A. Natale\",\n title = \"Radiofrequency ablation vs antiarrhythmic drugs as\n first-line treatment of symptomatic atrial\n fibrillation: a randomized trial.\",\n journal = \"JAMA\",\n year = \"2005\",\n month = jun,\n volume = \"293\",\n number = \"21\",\n pages = \"2634--2640\",\n robnote = \"afib CONTEXT: Treatment with antiarrhythmic drugs and\n anticoagulation is considered first-line therapy in\n patients with symptomatic atrial fibrillation (AF).\n Pulmonary vein isolation (PVI) with radiofrequency\n ablation may cure AF, obviating the need for\n antiarrhythmic drugs and anticoagulation. OBJECTIVE: To\n determine whether PVI is feasible as first-line therapy\n for treating patients with symptomatic AF. DESIGN,\n SETTING, AND PARTICIPANTS: A multicenter prospective\n randomized study conducted from December 31, 2001, to\n July 1, 2002, of 70 patients aged 18 to 75 years who\n experienced monthly symptomatic AF episodes for at\n least 3 months and had not been treated with\n antiarrhythmic drugs. INTERVENTION: Patients were\n randomized to receive either PVI using radiofrequency\n ablation (n=33) or antiarrhythmic drug treatment\n (n=37), with a 1-year follow-up. MAIN OUTCOME MEASURES:\n Recurrence of AF, hospitalization, and quality of life\n assessment. RESULTS: Two patients in the antiarrhythmic\n drug treatment group and 1 patient in the PVI group\n were lost to follow-up. At the end of 1-year follow-up,\n 22 (63\\%) of 35 patients who received antiarrhythmic\n drugs had at least 1 recurrence of symptomatic AF\n compared with 4 (13\\%) of 32 patients who received PVI\n (P<.001). Hospitalization during 1-year follow-up\n occurred in 19 (54\\%) of 35 patients in the\n antiarrhythmic drug group compared with 3 (9\\%) of 32\n in the PVI group (P<.001). In the antiarrhythmic drug\n group, the mean (SD) number of AF episodes decreased\n from 12 (7) to 6 (4), after initiating therapy (P =\n .01). At 6-month follow-up, the improvement in quality\n of life of patients in the PVI group was significantly\n better than the improvement in the antiarrhythmic drug\n group in 5 subclasses of the Short-Form 36 health\n survey. There were no thromboembolic events in either\n group. Asymptomatic mild or moderate pulmonary vein\n stenosis was documented in 2 (6\\%) of 32 patients in\n the PVI group. CONCLUSION: Pulmonary vein isolation\n appears to be a feasible first-line approach for\n treating patients with symptomatic AF. Larger studies\n are needed to confirm its safety and efficacy.\",\n bibdate = \"Thu Jun 28 00:49:02 2007\",\n}\n\n","author_short":["Wazni, O.","Marrouche, N.","Martin, D.","Verma, A.","Bhargava, M.","Saliba, W.","Bash, D.","Schweikert, R.","Brachmann, J.","Gunther, J.","Gutleben, K.","Pisano, E.","Potenza, D.","Fanelli, R.","Raviele, A.","Themistoclakis, S.","Rossillo, A.","Bonso, A.","Natale, A."],"key":"RSM:Waz2005b","id":"RSM:Waz2005b","bibbaseid":"wazni-marrouche-martin-verma-bhargava-saliba-bash-schweikert-etal-radiofrequencyablationvsantiarrhythmicdrugsasfirstlinetreatmentofsymptomaticatrialfibrillationarandomizedtrial-2005","role":"author","urls":{},"downloads":0,"html":""},"search_terms":["radiofrequency","ablation","antiarrhythmic","drugs","first","line","treatment","symptomatic","atrial","fibrillation","randomized","trial","wazni","marrouche","martin","verma","bhargava","saliba","bash","schweikert","brachmann","gunther","gutleben","pisano","potenza","fanelli","raviele","themistoclakis","rossillo","bonso","natale"],"keywords":[],"authorIDs":[],"dataSources":["5HG3Kp8zRwDd7FotB"]}